Device Firms Weigh Pros And Cons Of FDA-CMS Parallel Review
This article was originally published in The Gray Sheet
Executive Summary
As FDA and CMS edge closer to a joint program for pre-market review and reimbursement decision-making, device and diagnostic firms are expressing wariness about participating.